CBIO · Insider trading · 13F holders · Congress trades
Crescent Biopharma, Inc. (CBIO)
Who is buying and selling CBIO: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 13
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $286K
- Congress trades, 12 months
- 0
CBIO at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 7 CBIO insiders filed 7 sales worth $286K on SEC Form 4, and no open-market purchases; 7 of the sales were pre-planned under Rule 10b5-1.
- 13 13F filers hold CBIO among their 50 largest positions, worth $294.1M combined. The biggest bets by portfolio weight are Fcpm III Services B.v. (4.0%), Fairmount Funds Management LLC (3.3%) and NEXTBio Capital Management LP (3.1%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
- No member of Congress has disclosed a trade in CBIO.
- CBIO last closed at $14.07 on Oct 29, 2026.
CBIO insider trading
Between Aug 1, 2026 and Oct 29, 2026, 7 CBIO insiders filed 7 sales worth $286K on SEC Form 4, and no open-market purchases; 7 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Brumm Joshua T | Chief Executive Officer, Director | Sale10b5-1 | 9,447 | $16.91 | $160K | SEC |
| Sep 18, 2026 | McNeill Jonathan | President and COO | Sale10b5-1 | 4,570 | $16.90 | $77K | SEC |
| Sep 18, 2026 | Pinkas Jan | Chief Scientific Officer | Sale10b5-1 | 658 | $17.90 | $12K | SEC |
| Sep 18, 2026 | Im Ellie Eunkyung | Chief Medical Officer | Sale10b5-1 | 623 | $17.90 | $11K | SEC |
| Sep 18, 2026 | Bispham Barbara Harlin | See Remarks | Sale10b5-1 | 620 | $17.90 | $11K | SEC |
| Sep 18, 2026 | Scalzo Richard William | Chief Financial Officer | Sale10b5-1 | 568 | $17.90 | $10K | SEC |
| Sep 18, 2026 | Lynch Ryan | See Remarks | Sale10b5-1 | 240 | $17.90 | $4K | SEC |
Who owns CBIO? Hedge funds and superinvestors
13 13F filers hold CBIO among their 50 largest positions, worth $294.1M combined. The biggest bets by portfolio weight are Fcpm III Services B.v. (4.0%), Fairmount Funds Management LLC (3.3%) and NEXTBio Capital Management LP (3.1%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Bvf Inc/ilInvestment manager | 1.3% | $49.5M | 2,748,763 | +0.0% shares | Q2 2026 |
| Fairmount Funds Management LLCHedge fund | 3.3% | $49.5M | 2,747,866 | +0.0% shares | Q2 2026 |
| Venrock Adviser, LLCHedge fund | 1.2% | $38.4M | 2,133,576 | +0.0% shares | Q2 2026 |
| Logos Global Management LPHedge fund | 1.5% | $34.2M | 1,900,000 | +293.8% shares | Q2 2026 |
| Fcpm III Services B.v.Hedge fund | 4.0% | $30.2M | 1,677,852 | +0.0% shares | Q2 2026 |
| Vestal Point Capital, LPHedge fund | 0.7% | $29.3M | 1,630,000 | +8.7% shares | Q2 2026 |
| Opaleye Management Inc.Hedge fund | 2.2% | $23.7M | 1,319,351 | +0.5% shares | Q2 2026 |
| Tang Capital Management LLCHedge fund | 1.0% | $20.9M | 1,160,000 | +0.0% shares | Q2 2026 |
| NEXTBio Capital Management LPHedge fund | 3.1% | $6.7M | 372,856 | +0.0% shares | Q2 2026 |
| Remedium Capital Partners, LLCInstitutional asset manager | 1.4% | $6.5M | 361,250 | New | Q2 2026 |
| Exome Asset Management LLCHedge fund | 1.4% | $2.3M | 127,769 | -16.6% shares | Q2 2026 |
| Sectoral Asset Management IncHedge fund | 1.5% | $2.2M | 121,300 | — | Q2 2026 |
| Stonepine Capital Management, LLCHedge fund | 0.5% | $720K | 40,000 | -52.9% shares | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 13). Screen CBIO in the grand portfolio →
CBIO stock trades by members of Congress
No member of Congress has disclosed a trade in CBIO.
CBIO questions and answers
Are insiders buying CBIO stock?
Between Aug 1, 2026 and Oct 29, 2026, 7 CBIO insiders filed 7 sales worth $286K on SEC Form 4, and no open-market purchases; 7 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own CBIO?
13 13F filers hold CBIO among their 50 largest positions, worth $294.1M combined. The biggest bets by portfolio weight are Fcpm III Services B.v. (4.0%), Fairmount Funds Management LLC (3.3%) and NEXTBio Capital Management LP (3.1%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
Has Congress traded CBIO?
No member of Congress has disclosed a trade in CBIO.
Who is the largest holder of CBIO?
Among 13F filers, Bvf Inc/il reports the largest CBIO position, $49.5M (2,748,763 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Fcpm III Services B.v.'s: 4.0% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.